Total Funding
68
25
Total FundingSeries B raised
Growth Score
-1 pts
Heat Score
9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
7727
AIRNA develops RNA editing technologies to create medicines for various diseases.
- Paul Vogel: Vice PresidentPast Role: AIRNA, Co-Founder and Interim CEO
- Kris Elverum: President and Chief Executive OfficerPast Role: 5AM Ventures, President and Chief Executive Officer
About the Company
AIRNA focuses on RNA editing technologies to develop innovative medicines aimed at treating various diseases. The company engages in research and development to create therapeutic solutions that target genetic disorders, offering potential functional cures. Airna's approach involves utilizing advanced RNA editing techniques to repair or modify
genetic sequences, thereby addressing both rare and common health conditions. The team is committed to scientific collaboration and innovation, striving to enhance patient outcomes through their work in biotechnology. By leveraging cutting-edge methodologies, Airna contributes to the evolving landscape of genetic medicine.
